A recent study indicates that patients taking statins have a higher risk of developing cataracts.
Formulary Watch
Latest News
Today's Top Stories
All News
Advertisement
Recent FDA Approvals (through August 2012) related to (CSL Limited, GlaxoSmithKline Biologicals, ID Biomedical Corp, MedImmune Vaccines, Novartis Vaccines and Diagnostics Limited, Sanofi Pasteur, Genentech, Talon Therapeutics, Amarin, Regeneron Pharmaceuticals, Horizon Pharma, Forest Pharmaceuticals, Onyx Pharmaceuticals, Novartis, Pfizer, Sagent Pharmaceuticals)
Belviq (Lorcaserin): A 5-HT2C receptor agonist indicated to treat certain overweight or obese adults
By
New molecular entity: FDA approved Lorcaserin (Belviq, Arena Pharmaceuticals GMBH), as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index deemed obese and the presence of at least 1 weight-related comorbid condition.
A significant number of men who developed persistent sexual side effects from taking finasteride (Propecia and Proscar) also suffer from depressive symptoms and suicidal thoughts, according to a study published online in the Journal of Clinical Psychiatry.
Incretin-based therapies are now the most promising therapies for type 2 diabetes.
Teduglutide is a recombinant analog of human glucagon-like peptide-2 that is awaiting FDA approval for the treatment of short bowel syndrome (SBS) as a once-daily subcutaneous injection.
FDA approved enzalutamide (Xtandi, Astellas Pharma U.S. Inc. and Medivation) to treat men with late-stage (metastatic) castration-resistant prostate cancer that has spread or recurred, even with medical or surgical therapy to minimize testosterone.
Growth hormone-releasing hormone has favorable effects on cognition in healthy older adults and those with mild cognitive impairment, according to a study published online in the August issue of the Archives of Neurology.
Aminoglycoside-loaded bone cement implants, frequently used in orthopedic surgery, may result in systemic effects that raise aminoglycoside serum concentrations and lead to acute kidney injury, according to a study published July 3 in The Annals of Pharmacotherapy.
Systemic corticosteroid monotherapy of prednisone is not effective for patients with acute rhinosinusitis, according to a study published in the August 7 issue of the Canadian Medical Association Journal.
Advertisement
Vitamin D deficiency in critically ill children may make them more vulnerable to severe illnesses, according to 2 studies that were published ahead of the September print issue of Pediatrics.
FDA issued a Drug Safety Communication on sildenafil (Revatio, Pfizer), following the observation in a long-term extension of a clinical trial in pediatric patients with pulmonary arterial hypertension of an increase in mortality with increasing Revatio dose.
Children with cystic fibrosis who are taking ivacaftor (Kalydeco) may be at potential risk for cataracts, according to an FDA notification.
FDA approved linaclotide (Linzess, Ironwood Pharmaceuticals and Forest) to treat chronic idiopathic constipation and to treat irritable bowel syndrome with constipation in adults.
FDA has approved tbo-filgrastim (Sicor Biotech UAB, a member of Teva Corporation), or XM02 filgrastim, the first new granulocyte colony-stimulating factor to be approved in the United States in more than 10 years to reduce the time certain patients receiving cancer chemotherapy experience severe neutropenia.
FDA has approved everolimus tablets for oral suspension (Afinitor Disperz, Novartis), a new pediatric dosage form of the anti-cancer drug everolimus (Afinitor, Novartis) used to treat a rare brain tumor called subependymal giant cell astrocytoma.
FDA has approved elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg (Stribild, Gilead Sciences), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.
FDA has approved the supplemental New Drug Application for tapentadol extended-release tablets (Nucynta ER, Janssen), an oral analgesic taken twice daily, for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time.
Long-term use of proton pump inhibitors (PPI) may not significantly influence the development of osteoporosis, according to a recent study published July 10 in The American Journal of Gastroenterology.
Higher starting doses of allopurinol to treat gout may increase the risk for allopurinol hypersensitivity syndrome, according to a study published in the August 2012 issue of Arthritis & Rheumatism.
The use of generic prescription drugs instead of their brand-name counterparts has saved Americans and the nation's healthcare system $1.07 trillion over 10 years ending in 2011, according to the results of a study commissioned by the Generic Pharmaceutical Association.
A National Diabetes Care Commission will be established if new legislation introduced in the US Senate is passed.
FDA has approved Watson’s lidocaine topical patch 5%, the first generic version of Lidoderm (Endo) for the relief of pain associated with post-herpetic neuralgia.
FDA has approved buprenorphine and naloxone (Suboxone, Reckitt Benckiser Pharmaceuticals) sublingual film in the 4-mg and 12-mg strengths for the maintenance treatment of dependence on prescription opioid painkillers and heroin.
FDA approved Mylan Pharmaceutical's 15-mg, 30-mg, and 45-mg pioglitazone hydrochloride tablets, the first generic version of Actos (Takeda), along with diet and exercise to improve blood glucose control in adults with type 2 diabetes.
FDA has placed a partial clinical hold on Idenix Pharmaceuticals' nucleotide polymerase inhibitor under development for the treatment of hepatitis C virus.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
How new psoriasis, alopecia and atopic dermatitis therapies stood out at Fall Clinical Derm 2025
2
UC Davis develops new drug for bladder cancer patients
3
The FDA proposes ditching comparative efficacy studies for biosimilars
4
Misdiagnosis of Type 1 diabetes remains a major problem, despite advances
5